DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant

Vaccine

Volumn 24, Issue 14, 2006, Pages 2643-2655

  Bellier, Bertrand ^a   Dalba, Charlotte ^b   Clerc, Béatrice ^a   Desjardins, Delphine ^a   Drury, Rosybel ^c   Cosset, François Loïc ^c   Collins, Mary ^d   Klatzmann, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b EPIXIS SA   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cytotoxic response; DNA vaccine; Protective immunity; VLP

Indexed keywords

DNA VACCINE; EPITOPE; FREUND ADJUVANT; GAG PROTEIN; IMMUNOLOGICAL ADJUVANT; LYSYLALANYLVALYLTYROSYLASPARAGINYLPHENYLALANYLALANYLTHREONYLCYSTEINE; PEPTIDE FRAGMENT; PLASMID DNA; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG DESIGN; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKEMIA; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; T LYMPHOCYTE; VIRUS MUTATION; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE; LEUKEMIA VIRUS, MURINE; MICE; MICE, INBRED C57BL; RETROVIRIDAE; VACCINES, DNA;

EID: 33344457763     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.11.034     Document Type: Article

References (41)

1. D.M. Harper, E.L. Franco, and C. Wheeler Efficacy of a bivalent LI virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 9447 2004 1757 1765
2. L.L. Villa, R.L. Costa, and C.A. Petta Prophylactic quadrivalent human papillomavirus (types 6 11 16 and 18) LI virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Lancet Oncol 6 5 2005 271 278
3. M.F. Bachmann, T.M. Kundig, C.P. Kalberer, H. Hengartner, and R.M. Zinkernagel Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses J Virol 67 7 1993 3917 3922
4. M.F. Bachmann, U.H. Rohrer, T.M Kundig, K. Burki, H. Hengartner, and R.M. Zinkernagel The influence of antigen organization on B cell responsiveness Science 262 5138 1993 1448 1451
5. P. Lenz, P.M. Day, and Y.Y. Pang Papillomavirus-like particles induce acute activation of dendritic cells J Immunol 166 9 2001 5346 5355
6. R. Noad, and P. Roy Virus-like particles as immunogens Trends Microbiol 11 9 2003 438 444
7. J. Weber, R. Cheinsong-Popov, and D. Callow Immunogenicity of the yeast recombinant pl7/p24:Ty virus-like particles (p24-VLP) in healthy volunteers Vaccine 13 9 1995 831 834
8. C. Sedlik, M. Saron, J. Sarraseca, I. Casal, and C. Leclerc Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells Proc Natl Acad Sci USA 94 14 1997 7503 7508
9. K. Murata, M. Lechmann, M. Qiao, T. Gunji, H.J. Alter, and T.J. Liang Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection Proc Natl Acad Sci USA 100 11 2003 6753 6758
10. B.E. Clarke, S.E. Newton, and A.R. Carroll Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein Nature 330 6146 1987 381 384
11. P. Pumpens, R. Razanskas, and P. Pushko Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes Intervirology 45 1 2002 24 32
12. X. Chen, M. Li, X. Le, W. Ma, and B. Zhou Recombinant hepatitis B core antigen carrying preSl epitopes induce immune response against chronic HBV infection Vaccine 22 3-4 2004 439 446
13. I.K. Srivastava, and M.A. Liu Gene vaccines Ann Intern Med 138 7 2003 550 559
14. M.A. Liu DNA vaccines: a review J Intern Med 253 4 2003 402 410
15. D.C. Jackson, A.W. Pure ell, C.J. Fitzmaurice, W. Zeng, and D.N. Hart The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer Curr Drug Targets 3 2 2002 175 196
16. F.M. Lemoine, M. Mesel-Lemoine, and M. Cherai Efficient transduction and selection of human T-lymphocytes with bicistronic Thyl/HSVl-TK retroviral vector produced by a human packaging cell line J Gene Med 6 4 2004 374 386
17. F. Wendling, P. Varlet, M. Charon, and P. Tambourin MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice Virology 149 2 1986 242 246
18. Y. Soneoka, S.M. Kingsman, and A.J. Kingsman Mutagenesis analysis of the murine leukemia virus matrix protein: identification of regions important for membrane localization and intracellular transport J Virol 71 7 1997 5549 5559
19. B. Bellier, V. Thomas-Vaslin, M.F. Saron, and D. Klatzmann Turning immunological memory into amnesia by depletion of dividing T cells Proc Natl Acad Sci USA 100 25 2003 15017 15022
20. P. Noguiez-Hellin, M.R. Meur, J.L. Salzmann, and D. Klatzmann Plasmoviruses: nonviral/viral vectors for gene therapy Proc Natl Acad Sci USA 93 9 1996 4175 4180
21. H.G. Gottlinger, J.G. Sodroski, and W.A. Haseltine Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1 Proc Natl Acad Sci USA 86 15 1989 5781 5785
22. M. Andrawiss, Y. Takeuchi, L. Hewlett, and M. Collins Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of Gag-Gag interactions and membrane association J Virol 77 21 2003 11651 11660
23. G. Zelinskyy, S. Balkow, S. Schimmer, K. Schepers, M.M. Simon, and U. Dittmer Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection Virology 330 2 2004 365 374
24. U. Dittmer, D.M. Brooks, and K.J. Hasenkrug Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection Nat Med 5 2 1999 189 193
25. U. Dittmer, and K.J. Hasenkrug Different immunological requirements for protection against acute versus persistent Friend retrovirus infections Virology 272 1 2000 177 182
26. U. Dittmer, B. Race, and K.J. Hasenkrug Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus J Virol 73 10 1999 8435 8440
27. S.B. Wong, and R.F. Siliciano Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice J Virol 79 3 2005 1701 1712
28. D. Marsac, D. Loirat, C. Petit, O. Schwartz, and M.L. Mchel Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles J Virol 76 15 2002 7544 7553
29. M.J. McCluskie, C.L. Brazolot Millan, and R.A. Gramzinski Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates Mol Med 5 5 1999 287 300
30. K. Ito, N. Shinohara, and S. Kato DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response Mol Immunol 39 14 2003 847 854
31. S. Steidl, S. Schule, and M.D. Muhlebach Genetic engineering of onco/lentivirus hybrids results in formation of infectious but not of replication-competent viruses J Gen Virol 85 Pt 3 2004 665 678
32. S.C. Kayman, H. Park, M. Saxon, and A. Pinter The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system J Virol 73 3 1999 1802 1808
33. K. Sliva, O. Erlwein, A. Bittner, and B.S. Schnierle Murine leukemia virus (MLV) replication monitored with fluorescent proteins Virol J 1 1 2004 14
34. R. Mariani, G. Rutter, M.E. Harris, T.J. Hope, H.G. Krausslich, and N.R. Landau A block to human immunodeficiency virus type 1 assembly in murine cells J Virol 74 8 2000 3859 3870
35. W. Akahata, Z.Y. Yang, and G.J. Nabel Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine J Virol 79 1 2005 626 631
36. R.J. Messer, U. Dittmer, K.E. Peterson, and K.J. Hasenkrug Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection Proc Natl Acad Sci USA 101 33 2004 12260 12265
37. W. Baschong, L. Hasler, M. Haner, J. Kistler, and U. Aebi Repetitive versus monomeric antigen presentation: direct visualization of antibody affinity and specificity J Struct Biol 143 3 2003 258 262
38. V. Sandrin, S.J. Russell, and F.L. Cosset Targeting retroviral and lentiviral vectors Curr Top Microbiol Immunol 281 2003 137 178
39. V. Sandrin, D. Muriaux, J.L. Darlix, and F.L. Cosset Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses J Virol 78 13 2004 7153 7164
40. B. Bartosch, J. Dubuisson, and F.L. Cosset Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes J Exp Med 197 5 2003 633 642
41. X. Chen, M.T. Rock, and J. Hammonds Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses J Virol 79 9 2005 5537 5547